PERSON – Page 51

Lilly’s Tirzepatide Wins NICE Endorsement for Obesity Treatment with BMI and Weight Loss Conditions

1 year ago talkbio0Tagged Agonist, Body mass index procedure, Eli Lilly, Endorsement, Glucagon-Like Peptide-1 Receptor, Mounjaro, NICE, Nitroglycerin/Sodium Citrate/Ethanol Solution, Obesity, Zepbound

Lilly, tirzepatide, NICE endorsement, obesity treatment, BMI, weight loss, Zepbound, Mounjaro, GLP-1 receptor agonist

GSK Acquires Oligonucleotide Partner Elsie for Up to $50 Million

1 year ago talkbio0Tagged Acquisition (action), Elsie Biotechnologies, oligonucleotide platform, SmithKline Beecham

GSK, Elsie Biotechnologies, oligonucleotide platform, acquisition, biotech, pharmaceuticals

Lilly Initiates Search for New CFO Following Anat Ashkenazi’s Departure to Alphabet

1 year ago talkbio0Tagged Alphabet, Ashkenazi, Biopharma, CFO, Eli, Eli Lilly, Google, Pichai, Ruth, Science of Anatomy, Tech Industry

Anat Ashkenazi, CFO, Eli Lilly, Alphabet, Google, Ruth Porat, Sundar Pichai, Financial Leadership, Biopharma, Tech Industry

ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition

1 year ago talkbio0Tagged Acquisition (action), Alphamab, ArriVent, Biotechnology, financing characteristics, portfolio, therapeutic autologous dendritic cells

ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing

Amarin Names New CEO Aaron Berg Following Patrick Holt’s Resignation

1 year ago talkbio0Tagged Aaron Berg, Amarin, CEO, Holt, Leadership, Patrick, resignation, Transition Mutation

Amarin, CEO, Patrick Holt, Aaron Berg, Resignation, Leadership Transition

Brandon Capital Raises $180M Fund to Boost Australia and New Zealand Biotechs

1 year ago talkbio0Tagged Australia, biotechs, Brandon, Capital, New Zealand, scale-ups, startups, venture

Brandon Capital, biotechs, Australia, New Zealand, life sciences, venture capital, fund, startups, scale-ups

FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###

1 year ago talkbio0Tagged Approved, Attention deficit hyperactivity disorder, clonidine, Extended Release Suspension, hydrochloride, Liquid medication, LiquiXR, Non-stimulant, Onyda, Pediatric brand name, Svalbard, Technology, Tris Pharma, United States Food and Drug Administration

Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology

Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###

1 year ago talkbio0Tagged Autoimmune Diseases, Batoclimab, Biological Factors, FCGRT gene, FcRn, Immunovant, IMVT-1402, Inhibitor, Roivant

Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

1 year ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

FDA Approves Amgen’s Bkemv, First Interchangeable Biosimilar to Soliris for Rare Blood Disorders ###

1 year ago talkbio0Tagged Alexion, amgen, Approved, AstraZeneca, Atypical, Atypical Hemolytic Uremic Syndrome, Biosimilars, Bkemv, Hemolytic-Uremic Syndrome, Infrequent, interchangeable, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Soliris, United States Food and Drug Administration

Bkemv, Soliris, FDA approval, Interchangeable biosimilar, Rare blood disorders, Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Amgen, AstraZeneca, Alexion Pharmaceuticals